Physician profile
John R Diaz
NPI 1588616072
$58,650.35
in general payments reported to CMS, 2019-2025
56 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,866 · 2020: $27K · 2021: $22K · 2022: $2,232 · 2023: $2,490 · 2024: $1,789 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,584.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaneka Medical America LLC | $46,045.63 | 2019-2021 | |
| Amgen INC. | $1,608.17 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $1,319.61 | 2019-2024 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $1,005.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $731.55 | 2019-2025 | Evkeeza, Praluent |
| Novartis Pharmaceuticals Corporation | $683.19 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $657.44 | 2019-2024 | Synjardy, Tradjenta, Jardiance |
| Merck Sharp & Dohme LLC | $611.77 | 2019-2024 | Gardasil 9, Belsomra, Capvaxive |
| Lilly USA, LLC | $597.21 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $409.00 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $401.85 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $394.65 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $391.85 | 2019-2024 | Livalo, Seglentis |
| Tepha INC | $375.53 | 2019-2020 | |
| Amarin Pharma, INC. | $363.98 | 2019-2022 |
Show all 55 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.